Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
ApexOnco Front Page
Recent articles
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
In first-line SCLC BNT327 looks better than Tecentriq, but data will need to be replicated outside China.
Akeso scored in the Harmoni-A trial, and now Summit must do the same in Harmoni.
On key measures Keynote-D77 shows subcutaneous delivery to be the equal of IV.
Ikena, Senti and others look to clinical presentations at AACR.
The anti-PD-1 x CTLA-4 bispecific impresses in cervical cancer, but US plans are on ice.
The company talks up Rybrevant plus Lazcluze’s disease-modifying potential, but still has much to prove.
